ROSEN, A LEADING AND LONGSTANDING FIRM, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NERV
08 janv. 2021 17h08 HE
|
The Rosen Law Firm PA
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017...
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT
01 janv. 2021 19h15 HE
|
The Rosen Law Firm PA
NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
01 déc. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action – ZSAN
18 nov. 2020 13h08 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13,...
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
20 août 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NDA submission on track for 4Q 2020 NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
13 juil. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NDA submission on track for 4Q 2020 NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
09 mars 2020 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety...
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
03 févr. 2020 09h00 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
23 déc. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study
04 nov. 2019 07h00 HE
|
Trevena Inc.
Company expects to resubmit NDA for oliceridine in Q1 2020 Acute migraine proof-of-concept study for TRV250 initiated Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04,...